{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T05:34:45Z","timestamp":1786772085742,"version":"build-2736575974"},"reference-count":15,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,4,25]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Ocrelizumab is an anti-CD20 monoclonal antibody widely used in the treatment of multiple sclerosis (MS). Although rare, ocrelizumab-induced colitis is a recognised and potentially severe condition that may require life-saving surgical intervention if left untreated. Accurate diagnosis requires the exclusion of infective colitis or classical inflammatory bowel disease (IBD). Prolonged depletion of the CD20-positive B cell population by ocrelizumab may prolong the symptomatic trajectory and complicate the diagnosis. The lack of comprehensive data on ocrelizumab-induced colitis makes acute medical management of affected patients particularly challenging. This report details the case of a woman with steroid-refractory ocrelizumab-induced colitis, managed effectively with ciclosporin therapy in the salvage setting. Monitoring therapeutic drug levels, monitoring for neurotoxicity and early multidisciplinary team involvement facilitated safe titration of ciclosporin.<\/jats:p>","DOI":"10.1136\/bcr-2025-271164","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:20:23Z","timestamp":1784730023000},"page":"e271164","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Ocrelizumab-induced colitis acutely managed with ciclosporin"],"prefix":"10.1136","volume":"19","author":[{"given":"Stephanie","family":"Dimovski","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The Royal Melbourne Hospital, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddison","family":"Terlato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Royal Melbourne Hospital, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P","family":"Segal","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Royal Melbourne Hospital, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"2026072207201624000_19.7.e271164.1","doi-asserted-by":"crossref","first-page":"104763","DOI":"10.1016\/j.msard.2023.104763","article-title":"Anti-CD20 monoclonal antibody (mAb) therapy and colitis: A case series and review","volume":"75","author":"Tolaymat","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"2026072207201624000_19.7.e271164.2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1177\/13524585231195854","article-title":"Immune-mediated colitis associated with ocrelizumab: A new safety risk","volume":"29","author":"Kim","year":"2023","journal-title":"Mult Scler"},{"key":"2026072207201624000_19.7.e271164.3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/his.15120","article-title":"Histologic manifestations of ocrelizumab-associated intestinal and hepatic injury in patients with multiple sclerosis","volume":"84","author":"Challa","year":"2024","journal-title":"Histopathology"},{"key":"2026072207201624000_19.7.e271164.4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.4103\/aian.aian_608_24","article-title":"Organizing Pneumonia and Immunomediated Colitis Associated with Ocrelizumab Treatment","volume":"28","author":"Garc\u00eda-Est\u00e9vez","year":"2025","journal-title":"Ann Indian Acad Neurol"},{"key":"2026072207201624000_19.7.e271164.5","doi-asserted-by":"crossref","first-page":"S1662","DOI":"10.14309\/01.ajg.0000959024.43323.6e","article-title":"S2346\u2003Ocrelizumab Induced Colitis: A Rare Clinical Entity Mimicking Cytomegalovirus Colitis","volume":"118","author":"Thakurdesai","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026072207201624000_19.7.e271164.6","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1530438","article-title":"Ocrelizumab-induced colitis-critical review and case series from a Romanian cohort of MS patients","volume":"16","author":"Vod\u0103","year":"2025","journal-title":"Front Neurol"},{"key":"2026072207201624000_19.7.e271164.7","first-page":"28","article-title":"Revisiting cyclosporine in the age of biologics: update on efficacy and mechanism of action","volume":"2010","author":"Bhutani","year":"2010","journal-title":"Prac Dermatol"},{"key":"2026072207201624000_19.7.e271164.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)01214-9"},{"key":"2026072207201624000_19.7.e271164.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02552.x"},{"key":"2026072207201624000_19.7.e271164.10","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-313060"},{"key":"2026072207201624000_19.7.e271164.11","first-page":"00106","article-title":"Effectiveness and Safety of Janus Kinase Inhibitors in Acute Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis","volume":"Feb 12","author":"Jena","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026072207201624000_19.7.e271164.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.09.002"},{"key":"2026072207201624000_19.7.e271164.13","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000000832","article-title":"Ozanimod Maintenance Therapy After Cyclosporine Induction in Acute Severe Ulcerative Colitis","volume":"9","author":"Cohen","year":"2022","journal-title":"ACG Case Rep J"},{"key":"2026072207201624000_19.7.e271164.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033617"},{"key":"2026072207201624000_19.7.e271164.15","doi-asserted-by":"crossref","first-page":"i092","DOI":"10.1093\/ecco-jcc\/jjab232.082","article-title":"DOP43 Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True North","volume":"16","author":"Siegmund","year":"2022","journal-title":"J Crohns Colitis"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-271164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:20:24Z","timestamp":1784730024000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-271164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":15,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,22]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bcr-2025-271164"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-271164","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}